Skip to main content

Table 2 Tumor features

From: A pilot study on the impact of known drug-drug interactions in cancer patients

Breast cancer 43 %
 Invasive ductal carcinoma (IDC): Stage II (84 %) Stage III (12 %)
 Profiles: Luminal A (48.8 %), Luminal B/HER2- (8.7 %), Luminal B/HER2+ (17.4 %), HER2+/ER- (16.0 %) and Triple Negative (7.1 %);
Colorectal tumors 27 %:
 Adenocarcinomas, Stage IIa (25 %) Stage IIb (75 %)
Head and neck tumors 18 %
 Larynx (Squamous), Stage I (21 %) Stage II (79 %)
 Pharynx (HPV+), Stage I (93 %) Stage II (7 %)
Others 12 %
 Bladder (Stage I)
 Prostate (Gleason score 7)